HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Salvage combination chemotherapy with 5-fluorouracil and actinomycin D for patients with refractory, high-risk gestational trophoblastic tumors.

AbstractBACKGROUND:
The objective of this study was to evaluate the efficacy and toxicity of a high-dose 5-fluorouracil and actinomycin D regimen (the FA regimen) as salvage chemotherapy for patients with high-risk gestational trophoblastic tumors (GTTs).
METHODS:
From 1985 to 1997, 10 patients with refractory, high-risk GTTs were treated with the FA regimen at Chiba University Hospital. Of those 10 patients, 7 patients developed drug resistance to methotrexate, etoposide, and actinomycin D combination chemotherapy (the MEA regimen); 1 patient developed recurrent disease after receiving the MEA regimen; and 2 patients developed recurrent disease after receiving combination chemotherapy with etoposide, methotrexate, and actinomycin D alternating with cyclophosphamide and vincristine (the EMA/CO regimen). The hematologic toxicity of the FA regimen was graded at every chemotherapy course.
RESULTS:
With the FA regimen, the survival rate was 80.0% (8 of 10 patients) for a mean follow-up of 10 years. Two patients died due to multidrug resistance, and two patients subsequently developed recurrent disease. The two patients with recurrent disease were successfully salvaged again with the MEA regimen. The toxicity of the FA regimen was evaluated in 78 cycles. Myelosuppression seemed to be the dose-limiting toxicity, and the incidences of World Health Organization Grade 4 leukocytopenia and thrombocytopenia were 6.4% and 3.8%, respectively, of 78 cycles.
CONCLUSIONS:
Although etoposide-containing chemotherapy is currently the most effective and well-tolerated regimen for patients with high-risk GTTs, 20-30% of patients develop resistance to etoposide-containing regimens. Salvage combination chemotherapy with FA is effective for these patients with refractory disease, and the toxicity is predictable and manageable.
AuthorsHideo Matsui, Kiyomi Suzuka, Yoshinori Iitsuka, Koji Yamazawa, Naotake Tanaka, Akira Mitsuhashi, Katsuyoshi Seki, Souei Sekiya
JournalCancer (Cancer) Vol. 95 Issue 5 Pg. 1051-4 (Sep 01 2002) ISSN: 0008-543X [Print] United States
PMID12209690 (Publication Type: Journal Article)
CopyrightCopyright 2002 American Cancer Society.
Chemical References
  • Dactinomycin
  • Fluorouracil
Topics
  • Adult
  • Dactinomycin (administration & dosage)
  • Drug Resistance, Multiple
  • Female
  • Fluorouracil (administration & dosage)
  • Humans
  • Leukopenia (chemically induced)
  • Neoplasm Recurrence, Local (drug therapy)
  • Pregnancy
  • Retrospective Studies
  • Risk Factors
  • Salvage Therapy
  • Survival Analysis
  • Thrombocytopenia (chemically induced)
  • Trophoblastic Neoplasms (drug therapy, pathology)
  • Uterine Neoplasms (drug therapy, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: